ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
7 957,57
0,54%
Dow Jones
38 675,68
1,18%
DAX
18 001,60
0,54%
Brent Oil
82,765
0,00%
Bitcoin
63 108,91
0,35%
Registration Strip Icon for charts Inscrivez-vous pour des graphiques en temps réel, des outils d'analyse et des prix.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Altamira Therapeutics Ltd (CYTO)

  7. Altamira Therapeutics Ltd (CYTO) Actualités

CYTO Altamira Therapeutics Ltd

1,58
-0,06 (-3,66%)
04 Mai 2024 - Fermé
Retardé de 15 minutes
Nom Action Symbole Action Marché Type
Altamira Therapeutics Ltd CYTO NASDAQ Action ordinaire
  Variation Action Variation Action% Cours Dernier Dernier échange
Upgrade Icon
-0,06 -3,66% 1,58 06:00:05
Ouverture Plus Bas Plus Haut Prix de clôture Clôture Veille
1,62 1,60 1,66 1,64 1,64
plus d'informations sur les cotations »

Actualités Recentes

Date Heure Source Titre
01/5/202414:47GLOBEAltamira Therapeutics Announces Filing of Provisional Patent..
24/4/202414:47GLOBEAltamira Therapeutics Announces Publication of Positive..
10/4/202414:00GLOBEAltamira Therapeutics Provides Business Update, Reports Full..
04/4/202414:45GLOBEAltamira Therapeutics to Host Full Year 2023 Financial..
25/3/202413:47GLOBEAltamira Therapeutics Announces Collaboration with..
07/2/202414:47GLOBEAltamira Therapeutics’ Peptide-Based Delivery Platform Shown..
24/1/202414:47GLOBEAltamira Therapeutics Files Second Provisional Patent..
22/1/202423:02EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
22/1/202406:15EDGAR2Form EFFECT - Notice of Effectiveness
19/1/202422:45EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
19/1/202422:40EDGAR2Form 424B5 - Prospectus [Rule 424(b)(5)]
19/1/202422:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
08/1/202423:02EDGAR2Form F-3 - Registration statement by foreign private issuers
08/1/202414:47GLOBEAltamira Therapeutics to Present at 3rd Annual mRNA-Based..
29/12/202314:47GLOBEAltamira Therapeutics Regains Compliance with Nasdaq Minimum..
11/12/202314:01EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/12/202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
11/12/202314:00GLOBEAltamira Therapeutics Provides Investor and Business Update
08/12/202315:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
05/12/202318:54GLOBEAltamira Therapeutics to Host Investor & Business Update..
29/11/202316:20GLOBEAltamira Therapeutics Regains Compliance with Nasdaq Minimum..
22/11/202322:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
21/11/202314:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
17/11/202315:04GLOBEAltamira Therapeutics Announces Partial Spin-Off of Bentrio®..
10/11/202314:47GLOBEAltamira Therapeutics Announces European Patent Office..
31/10/202321:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
04/10/202315:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
14/9/202314:47GLOBEAltamira Therapeutics Reports Additional Significant..
12/9/202313:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
12/9/202313:30GLOBEAltamira Therapeutics Provides Business Update and First..
06/9/202314:47GLOBEAltamira Therapeutics to Host First Half 2023 Financial..
23/8/202314:47GLOBEAltamira Therapeutics to Present at H.C. Wainwright 25th..
21/8/202313:31EDGAR2Form 6-K/A - Report of foreign issuer [Rules 13a-16 and..
28/7/202313:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
26/7/202315:00EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
20/7/202314:47GLOBEAltamira Therapeutics and Pharma Nordic Collaborate for..
17/7/202314:47GLOBEAltamira Therapeutics Announces Publication of Positive..
11/7/202314:32EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..
07/7/202322:14EDGAR2Form 424B4 - Prospectus [Rule 424(b)(4)]
05/7/202314:47GLOBEAltamira Therapeutics Announces Collaboration with Heqet..
30/6/202312:30EDGAR2Form 6-K - Report of foreign issuer [Rules 13a-16 and..

Dernières Valeurs Consultées

NASDAQ
CYTO
Altamira Therapeutics
Delayed Upgrade Clock
ADVFN Logo

France
Société
Entreprise
Popular
Obtenir l'application

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés